Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Climb Bio (NASDAQ: CLYM) has granted an inducement equity award to a new employee under its 2025 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The award, granted on May 19, 2025, consists of a non-statutory stock option to purchase 120,000 shares of common stock at an exercise price of $1.27 per share, matching the closing price on Nasdaq Global Market. The option has a ten-year term and vests over four years, with 25% vesting after the first year and the remaining shares vesting in 36 monthly installments, contingent on continued employment.
Climb Bio (NASDAQ: CLYM) ha concesso un premio azionario di incentivazione a un nuovo dipendente nell'ambito del suo Piano di Incentivazione 2025, in conformità con la Regola 5635(c)(4) del Nasdaq. Il premio, assegnato il 19 maggio 2025, consiste in un'opzione azionaria non statutaria per acquistare 120.000 azioni ordinarie a un prezzo di esercizio di 1,27 $ per azione, corrispondente al prezzo di chiusura sul Nasdaq Global Market. L'opzione ha una durata di dieci anni e si matura in quattro anni, con il 25% che si matura dopo il primo anno e il restante 75% che si matura in 36 rate mensili, condizionato alla continuazione del rapporto di lavoro.
Climb Bio (NASDAQ: CLYM) ha otorgado un premio de acciones por incentivo a un nuevo empleado bajo su Plan de Incentivos 2025, conforme a la Regla 5635(c)(4) de Nasdaq. El premio, concedido el 19 de mayo de 2025, consiste en una opción sobre acciones no estatutaria para comprar 120,000 acciones ordinarias a un precio de ejercicio de $1.27 por acción, igualando el precio de cierre en Nasdaq Global Market. La opción tiene un plazo de diez años y se consolida en cuatro años, con un 25% consolidado tras el primer año y el resto en 36 cuotas mensuales, condicionado a la continuidad laboral.
Climb Bio (NASDAQ: CLYM)는 Nasdaq 상장 규칙 5635(c)(4)에 따라 2025년 유인 계획 하에 신규 직원에게 유인 주식 보상을 부여했습니다. 2025년 5월 19일에 부여된 이 보상은 비법정 스톡옵션으로, 120,000주의 보통주를 주당 $1.27의 행사가격으로 구매할 수 있는 권리입니다. 이는 Nasdaq 글로벌 마켓의 종가와 동일합니다. 옵션의 유효 기간은 10년이며, 4년에 걸쳐 권리가 발생합니다. 첫 해 후 25%가 확정되고, 나머지 주식은 36개월에 걸쳐 매월 분할하여 권리가 부여되며, 계속 고용이 조건입니다.
Climb Bio (NASDAQ : CLYM) a accordé une attribution d'actions d'incitation à un nouvel employé dans le cadre de son Plan d'Incitation 2025, conformément à la règle 5635(c)(4) du Nasdaq. Cette attribution, effectuée le 19 mai 2025, consiste en une option d'achat d'actions non statutaire portant sur 120 000 actions ordinaires au prix d'exercice de 1,27 $ par action, correspondant au cours de clôture sur le Nasdaq Global Market. L'option a une durée de dix ans et s'acquiert sur quatre ans, avec 25 % acquises après la première année et le reste en 36 versements mensuels, sous condition de maintien de l'emploi.
Climb Bio (NASDAQ: CLYM) hat einem neuen Mitarbeiter gemäß dem Inducement-Plan 2025 eine Anreizaktienauszeichnung gewährt, in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4). Die Auszeichnung, die am 19. Mai 2025 gewährt wurde, besteht aus einer nicht-statutären Aktienoption zum Kauf von 120.000 Aktien des Stammkapitals zu einem Ausübungspreis von 1,27 $ pro Aktie, entsprechend dem Schlusskurs am Nasdaq Global Market. Die Option hat eine Laufzeit von zehn Jahren und wird über vier Jahre erworben, wobei 25 % nach dem ersten Jahr und die restlichen Anteile in 36 monatlichen Raten vesten, vorausgesetzt die Beschäftigung wird fortgesetzt.
- None.
- None.
WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an inducement equity award to a new employee, pursuant to the Company’s 2025 Inducement Plan, as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity award was granted to one new employee on May 19, 2025, and consisted of a non-statutory stock option to purchase up to an aggregate of 120,000 shares of common stock of the Company. The option has an exercise price of
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com.
Investors and Media
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
What type of stock option did Climb Bio (CLYM) grant to its new employee?
What is the vesting schedule for CLYM's inducement grant announced on May 19, 2025?
What is the exercise price of Climb Bio's inducement grant issued in May 2025?
How long is the term of CLYM's inducement stock option grant?
